PROCEPT BioRobotics Future Growth
Future criteria checks 2/6
PROCEPT BioRobotics is forecast to grow earnings and revenue by 41.4% and 24.6% per annum respectively while EPS is expected to grow by 42.8% per annum.
Key information
41.4%
Earnings growth rate
42.8%
EPS growth rate
| Medical Equipment earnings growth | 17.8% |
| Revenue growth rate | 24.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 21 Aug 2024 |
Recent future growth updates
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Recent updates
Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?
Feb 27Procept Biorobotics announces $52M debt refinancing
Oct 10Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems
Sep 19Procept BioRobotics Has Resources To Ramp Up Commercialization
Sep 01Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
May 26Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues
May 10PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target
Mar 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 396 | -48 | N/A | N/A | 4 |
| 12/31/2025 | 305 | -77 | -66 | N/A | 7 |
| 12/31/2024 | 217 | -97 | -69 | N/A | 7 |
| 6/30/2024 | 177 | -104 | -109 | -92 | N/A |
| 3/31/2024 | 156 | -103 | -126 | -104 | N/A |
| 12/31/2023 | 136 | -106 | -133 | -108 | N/A |
| 9/30/2023 | 116 | -107 | -126 | -108 | N/A |
| 6/30/2023 | 102 | -105 | -122 | -109 | N/A |
| 3/31/2023 | 85 | -98 | -106 | -98 | N/A |
| 12/31/2022 | 75 | -87 | -83 | -80 | N/A |
| 9/30/2022 | 61 | -77 | -74 | -72 | N/A |
| 6/30/2022 | 50 | -69 | -65 | -65 | N/A |
| 3/31/2022 | 41 | -64 | -61 | -60 | N/A |
| 12/31/2021 | 34 | -60 | -58 | -57 | N/A |
| 9/30/2021 | 28 | -57 | -55 | -54 | N/A |
| 6/30/2021 | 21 | -55 | -53 | -52 | N/A |
| 3/31/2021 | 14 | -53 | -52 | -52 | N/A |
| 12/31/2020 | 8 | -53 | -49 | -48 | N/A |
| 12/31/2019 | 6 | -42 | -51 | -44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRCT's revenue (24.6% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: PRCT's revenue (24.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRCT's Return on Equity is forecast to be high in 3 years time